Lenacapavir
授权管线 · 长效注射剂（皮下） · 463.5 mg / 1.5 mL
授权管线US DMF II（在编）Confidentiality：高保密
- INN / Generic Name
- Lenacapavir
- Dosage Form
- 长效注射剂（皮下）
- Strength
- 463.5 mg / 1.5 mL
- Therapy Area
- Antivirals
- Indication
- HIV-1 感染（多重耐药，长效治疗方案）
- Current Status
- 原研已上市；仿制/授权管线开发中（专利期内）
- GMP Certification
- cGMP（自有基地）
- CEP
- No
- DMF Type
- US DMF II（在编）
- Stability Data
- 24 months
- BE Required
- Not required / waivable
- Registration Pathway
- NP（专利期后）/ 自愿许可路径
- MOQ
- 1 个项目
- Lead Time
- 180 天
- Price Range
- 授权 upfront US$ 800k-1.6M
Registrable Markets
BrazilMoroccoVietnamPeru
Process / Sequence / Exact Price
🔒 Sign a CDA to view process / price / customer
Per our compliance red line, before a CDA is signed we do not disclose sequences, full structures, detailed processes, real customer names or exact prices of pre-launch pipelines. Once you raise an RFQ, the system auto-generates a CDA template; upon admin approval the full data room unlocks.